Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CCX872-B · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CCX872-B | EXPERIMENTAL | 150 mg once or twice daily given orally for at least 12 weeks |
| Name | Type | Description |
|---|---|---|
| CCX872-B | DRUG | Tablets (oral administration) |
Inclusion Criteria: * Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastases * Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 * Anticipated life expectancy ≥ 12 weeks * Radiographically measurable disease acc. to RECIST ...
Top 20 of 68 competitors
CCX872-B is an investigational small molecule being studied for the treatment of pancreatic cancer, specifically pancreatic adenocarcinoma. It is currently in clinical development and has not been approved by the FDA. A Phase 1b trial has been completed to evaluate its safety and efficacy in patients with this condition.
CCX872-B is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is an investigational small molecule in Phase 1 clinical development for the treatment of pancreatic cancer.
CCX872-B is in Phase 1 clinical development. A Phase 1b study has been completed, and the drug remains investigational. It has not received FDA approval and is still undergoing clinical evaluation for the treatment of pancreatic cancer.
CCX872-B has been studied in one clinical trial, NCT02345408, titled 'Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma.' This trial was completed and enrolled 54 participants with pancreatic cancer in the United States and Netherlands.
CCX872-B is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for pancreatic cancer. The completed Phase 1b trial, NCT02345408, evaluated the drug in 54 patients, but it has not yet received regulatory approval.